

Appendix Table 3.
In hospital management and outcomes.

	Overall (n 2798)	Female (n 1111)	Male (n 1687)	P Value
O2 therapy	68.7% (1879/2736)	63.0% (684/1086)	72.4% (1195/1650)	<0.001
HFNC	18.3% (492/2686)	16.9% (180/1067)	19.3% (312/1619)	0.115
NIMV	14.5% (390/2684)	12.4% (133/1069)	15.9% (257/1615)	0.012
Invasive mechanical ventilation	6.3% (168/1646)	4.5% (48/1059)	7.6% (120/1587)	0.002
Pronation	9.2% (246/2665)	6.6% (70/1066)	11.0% (176/1599)	<0.001
Circulation support / ECMO	2.6% (69/2662)	1.9% (20/1066)	3.1% (49/1596)	0.057
Corticosteroids use	22.4% (604/2693)	18.6% (200/1076)	25.0% (404/1617)	<0.001
Chloroquine/HCQ use	84.5% (2306/2728)	84.4% (922/1092)	84.6% (1384/1636)	0.907
Antivirals	65.8% (1795/2726)	64.1% (699/1091)	67.0% (1096/1635)	0.110
Interferon	16.7% (448/2680)	15.1% (162/1071)	17.8% (286/1609)	0.072
Tocilizumab	6.8% (183/2681)	4.7% (50/1075)	8.3% (133/1606)	<0.001
Antibiotics	74.4% (1953/2625)	71.1% (740/1041)	76.6% (1213/1584)	0.002
ACE/ARB	17.9% (464/2598)	17.2% (179/1038)	18.3% (285/1560)	0.504
Anticoagulation in hospital	34.2% (956/2798)	34.7% (386/1111)	33.8% (570/1687)	0.131
Respiratory insufficiency	48.0% (1310/1731)	41.5% (451/1088)	52.3% (859/1643)	<0.001
Upper Respiratory tract infection	14.9% (392/2633)	14.5% (153/1057)	15.2% (239/1576)	0.626
Bilateral pneumonia	68.3% (1872/2739)	64.7% (705/1090)	70.8% (1167/1649)	<0.001
Sepsis	13.2% (356/2696)	11.7% (127/1081)	14.2% (229/1615)	0.068
SIRS	18.8% (500/2660)	14.6% (156/1069)	21.6% (344/1591)	<0.001
Bleeding	2.1% (55/2647)	1.3% (14/1067)	2.6% (41/1580)	0.023
Embolic event	1.6% (42/2655)	1.6% (17/1070)	1.6% (25/1585)	0.981
Skin rash	3.3% (32/984)	4.1% (16/393)	2.7% (16/591)	0.272
Heart failure	6.6% (177/2701)	5.9% (64/1085)	7.0% (113/1616)	0.260
Renal failure	16.9% (459/2712)	11.8% (128/1082)	20.3% (331/1630)	<0.001
Death	21.4% (598/2792)	18.2% (202/1109)	23.5% (396/1683)	0.001